Trofinetide

Major

Trofinetide Acetaminophen And Codeine Capital® & Codeine Explained Increased codeine and morphine exposure Details Trofinetide Colchicine Colcrys Explained Increased colchicine exposure and an increased risk of colchicine-related toxicity Details Trofinetide Simvastatin Flolipid Explained Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related toxicities Details Trofinetide Abemaciclib Verzenio Explained Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related toxicities Details Trofinetide Acalabrutinib Calquence Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related toxicities Details Trofinetide Atogepant Qulipta Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related toxicities Details Trofinetide Avapritinib Ayvakit Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related toxicities Details Trofinetide Avanafil Stendra Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related toxicities Details Trofinetide Bedaquiline Sirturo Increased bedaquiline exposure Details Trofinetide Bosutinib Bosulif Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related toxicities Details Trofinetide Budesonide Entocort Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related toxicities Details Trofinetide Budesonide Nasal Spray Rhinocort Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related toxicities Details Trofinetide Budesonide Oral Inhalation Pulmicort Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related toxicities Details Trofinetide Cobimetinib Cotellic Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related toxicities Details Trofinetide Cyclosporine Injection Atopica Increased sensitive CYP3A/P-gp substrate with NTI exposure and an increased risk of sensitive CYP3A/P-gp substrate with NTI substr... Details Trofinetide Cyclosporine Ophthalmic Cequa Increased sensitive CYP3A/P-gp substrate with NTI exposure and an increased risk of sensitive CYP3A/P-gp substrate with NTI substr... Details Trofinetide Dasatinib Phyrago Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related toxicities Details Trofinetide Digoxin Cardoxin® Increased digoxin exposure and an increased risk of digoxin-related adverse reactions Details Trofinetide Doxorubicin Adriamycin Increased doxorubicin exposure and an increased risk of doxorubicin-related adverse reactions Details Trofinetide Elacestrant Orserdu Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related toxicities Details Trofinetide Entrectinib Rozlytrek Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related toxicities Details Trofinetide Everolimus Afinitor Increased sensitive CYP3A/P-gp substrate with NTI exposure and an increased risk of sensitive CYP3A/P-gp substrate with NTI substr... Details Trofinetide Felodipine Plendil® Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related toxicities Details Trofinetide Finerenone Kerendia Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related toxicities Details Trofinetide Ibrexafungerp Brexafemme Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related toxicities Details Trofinetide Ibrutinib Imbruvica Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related toxicities Details Trofinetide Infigratinib Truseltiq Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related toxicities Details Trofinetide Ivabradine Corlanor Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related toxicities Details Trofinetide Loperamide Diamode Increased loperamide exposure and an increased risk of loperamide-related adverse reactions Details Trofinetide Lovastatin Altocor® Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related toxicities Details Trofinetide Lurasidone Latuda Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related toxicities Details Trofinetide Maraviroc Selzentry Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related toxicities Details Trofinetide Methylergonovine Methergine Increased methylergonovine exposure Details Trofinetide Midazolam Nasal Spray Nayzilam Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related toxicities Details Trofinetide Midazolam Injection Nayzilam Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related toxicities Details Trofinetide Midostaurin Rydapt Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related toxicities Details Trofinetide Mitapivat Aqvesme Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related toxicities Details Trofinetide Naloxegol Movantik Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related toxicities Details Trofinetide Nifedipine Adalat® Increased NIFEdipine exposure Details Trofinetide Nisoldipine Sular Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related toxicities Details